-
1.
Lindner A, Charra B, Sherrard DJ, et al.. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290:697–701.
-
2.
Ferrer Tomas R, Jara J Guías SEN. Riñón y Enfermedad Cardiovascular 2004; 24:21–26.
-
3.
Bover J, Ortiz F, Cabezas A, et al.. Nuevos conceptos sobre enfermedad renal crónica y sus implicaciones, Act Fund Puigvert 2004; 23:176–191.
-
4.
Pérez SG, Ortiz F, Ballarín J, Bover J. Enfermedad cardiovascular en pacientes con enfermedad renal crónica: modelo experimental para la evaluación del eje cardio-renal. Act Fund Puigvert 2006; 25:189–194.
-
5.
Ronco C, Haapio M, House AA, et al.. Cardiorenal syndrome, J Am Coll Cardiol 2008; 52:1527–1539.
-
6.
Levey AS, Beto JA, Coronado BE, et al.. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853–906.
-
7.
Sarnak MJ, Levey AS, Schoolwerth AC, et al.. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154–2169.
-
8.
Foley RN, Parfrey PS, Harnett JD, et al.. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49:1379–1385.
-
9.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1–266.
-
10.
Levey AS, Eckardt KU, Tsukamoto Y, et al.. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089–2100.
-
11.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension 2003; 42:1206–1252.
-
12.
Gracia S, Montañés R, Bover J, et al.. Recommendations for the use of equations to estimate glomerular filtration rate in adults. Spanish Society of Nephrology. Nefrologia 2006; 26:658–665.
-
13.
Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(12 Suppl).
-
14.
Bover J, Górriz JL, Martín de Francisco AL, et al.. Unawareness of the K/DOQI guidelines for bone and mineral metabolism in predialysis chronic kidney disease: results of the OSERCE Spanish multicenter-study survey. Nefrologia 2008; 28:637–643.
-
15.
Dikow R, Kihm LP, Zeier M, et al.. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004; 15:1530–1536.
-
16.
van Dokkum RP, Eijkelkamp WB, Kluppel AC, et al.. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15:3103–3110.
-
17.
Fernández-Llama P, Bover J. Is albuminuria a marker of arterial remodeling? J Hypertens 2008; 26:633–635.
-
18.
Ochodnicky P, de Zeeuw D, Henning RH, et al.. Endothelial function predicts the development of renal damage after combined nephrectomy and myocardial infarction. J Am Soc Nephrol 2006; 17(4 Suppl 2):S49–52.
-
19.
Fedulov AV, Ses TP, Gavrisheva NA, et al.. Serum TGF-β 1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure. Immunol Invest 2005; 34:143–152.
-
20.
Wong LS, Windt WA, Roks AJ, et al.. Renal failure induces telomere shortening in the rat heart. Neth Heart J 2009 May; 17(5):190–194.
-
21.
Brymora A, Flisiński M, Grześk G, et al.. Inflammation, malnutrition and vascular contraction in experimental chronic kidney disease. J Nephrol 2007; 20:423–429.
-
22.
Pérez S, Bernasconi A, Ballarín J, et al.. La enfermedad cardiovascular en pacientes con insuficiencia renal crónica: el eje cardiorenal. Rev Argent Cardiol 2008; 76:215–218.
-
23.
Pérez S, Ortiz F, Ballarín J, Bover J. Enfermedad cardiovascular en pacientes con enfermedad renal crónica: modelo experimental para la evaluación del eje cardio-renal. Act Fund Puigvert 2006; 25(4):189–194.
-
24.
Buzello M, Torniq J, Faulhaber J, et al.. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003; 14:311–316.
-
25.
Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. JAm Soc Nephrol 2005; 16:917–928.
-
26.
Li Y, Takemura G, Okada H, et al.. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Card Fail 2007; 13:155–162.
Experimental models of cardiorenal syndrome: from basic science to the clinic
Search for other papers by By Susana Pérez in
Current site
Google Scholar
PubMed
Search for other papers by Alejandro Bernasconi in
Current site
Google Scholar
PubMed
Search for other papers by Carlos Musso in
Current site
Google Scholar
PubMed
Search for other papers by Jordi Bover in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory